Leuprolide
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Using this Evidence Pack directly (no additional skills apply — this is a self-contained report-writing task per the v5 template instructions already provided). Below is the report.
Leuprolide: From GnRH-Agonist Hormone Suppression Therapy to Osteoarthritis
One-Sentence Summary
Leuprolide is a GnRH (LHRH) agonist historically used to suppress sex-hormone secretion in hormone-dependent conditions (e.g., androgen deprivation therapy in prostate cancer). The TxGNN model predicts it may be effective for Osteoarthritis, but this direction is supported by only 1 clinical trial and 1 publication, neither of which actually studies leuprolide in osteoarthritis — and the drug’s known pharmacology points in the opposite direction (GnRH agonists are associated with increased bone loss and joint pain, not improvement).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not extractable from Taiwan regulatory data (drug is not marketed/licensed in this dataset); pharmacological context indicates hormone-dependent conditions treated via androgen/estrogen suppression (e.g., ADT for prostate cancer) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 (model prediction only — no genuine disease-relevant studies) |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for leuprolide is flagged as a data gap in this evidence pack (DG002). Based on the pharmacological context available, leuprolide is a GnRH (LHRH) agonist that, with continuous administration, downregulates pituitary GnRH receptors and suppresses downstream sex-hormone (testosterone/estrogen) production — a mechanism used therapeutically in hormone-dependent conditions such as androgen deprivation therapy (ADT) for prostate cancer.
The TxGNN score of 0.9969 (rank 8002) reflects topological similarity within the knowledge graph rather than a validated pharmacological rationale for osteoarthritis. Critically, the mechanistic review embedded in this evidence pack notes that the known clinical effect of GnRH agonists on the musculoskeletal system runs opposite to what would be needed to treat osteoarthritis: long-term hormone suppression (as with ADT) is a well-documented cause of accelerated bone loss, osteoporosis, and arthralgia/myalgia — it does not alleviate joint disease. There is no known pathway by which leuprolide would reduce cartilage degeneration or joint inflammation.
For this reason, the mechanistic link should be read as a contradictory signal rather than supporting evidence. The single clinical trial and single publication retrieved for this pairing were both about metastatic prostate cancer and were captured only because they involve an LHRH analog — not because they studied osteoarthritis outcomes. This pattern is consistent with a false-positive prediction driven by graph co-occurrence rather than genuine therapeutic plausibility, and it should be treated with a high degree of skepticism.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00002881 | Phase 3 | Completed | N/A | Randomized trial of orchiectomy/LHRH analog + flutamide ± suramin/hydrocortisone in metastatic prostate cancer. No osteoarthritis endpoint; trial was matched only because it uses an LHRH analog. Relevance graded C (low/mismatched) — does not support the osteoarthritis prediction. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20133250 | 2010 | Case Report | Clinical Breast Cancer | Describes metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma. Unrelated to osteoarthritis; not relevant supporting evidence. |
US Market Information
Currently no marketing authorization records available — leuprolide is not marketed under this dataset (0 licenses on file), so no license/product table can be generated.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are all currently unavailable — a TFDA label/warnings lookup is flagged as a blocking data gap for safety pre-screening, see Next Steps.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 — the only “supporting” trial and publication are both about unrelated metastatic prostate cancer and were captured due to LHRH-analog keyword overlap, not genuine osteoarthritis relevance. More importantly, the known pharmacology of GnRH agonists (worsening bone loss/arthralgia via hormone suppression) contradicts rather than supports a therapeutic role in osteoarthritis, making this look like a likely false-positive TxGNN signal.
To proceed, the following is needed:
- TFDA/FDA label data on warnings and contraindications (currently a blocking data gap — required before any safety pre-screening, DG001)
- Verified mechanism-of-action documentation via DrugBank API (currently missing, DG002)
- Disease-specific pharmacological or preclinical rationale explaining how GnRH suppression could plausibly benefit osteoarthritis, given the contradictory clinical signal noted above
- If this candidate is still pursued, independent expert review to rule out a knowledge-graph artifact before any further investment
Note on secondary candidate: A second, lower-ranked prediction (pseudoachondroplasia, TxGNN score 99.69%, rank 8263) was also flagged for leuprolide but has zero supporting clinical trials or literature and an even weaker mechanistic rationale (a genetic/structural cartilage disorder with no known GnRH-pathway involvement). This candidate should also be held pending stronger evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.